Retirement investing does not have to be all about chasing the highest dividend yield.

I would still want businesses that can grow over time, while also providing some income along the way.

These three ASX shares would be on my list.

Wesfarmers Ltd (ASX: WES)

Wesfarmers is one of the first ASX shares I would consider.

The group owns businesses including Bunnings, Kmart, Officeworks, and Priceline, giving it several sources of earnings across different parts of the Australian economy.

For retirement investors, I like the combination of established businesses and room for further growth.

Bunnings has built a powerful position in home improvement, while Kmart continues to benefit from its focus on affordable products. Wesfarmers also has the financial strength to invest in existing businesses or pursue new opportunities when management sees attractive returns.

The company has also paid dividends consistently over many years.

Commonwealth Bank of Australia (ASX: CBA)

CBA would give me a more traditional source of income.

The bank generates substantial profits from its large customer base across home lending, deposits, business banking, and other financial services.

That has allowed it to return significant amounts of cash to shareholders through fully franked dividends.

Australian banking is a mature industry, so I would not expect rapid earnings growth.

But for retirement, I would be comfortable owning a high-quality business capable of producing substantial cash flow while still gradually increasing earnings over time.

CBA is rarely the cheapest bank on the ASX, but I would be willing to pay a little more for what I think is the strongest banking business in Australia.

Sigma Healthcare Ltd (ASX: SIG)

Sigma would be the more growth-focused choice of the three ASX shares.

Following its combination with Chemist Warehouse, the company now has exposure to one of Australia’s best-known pharmacy brands alongside a major pharmaceutical distribution operation.

I think there are several ways the business can become larger over the next decade.

Chemist Warehouse continues to expand its store network, while international markets such as New Zealand and the United Kingdom provide additional room for growth.

Sigma can also benefit from the wider pharmacy ecosystem, including distribution, retail sales, online channels, and relationships with suppliers.

While its dividend yield is not the largest, if the company can expand earnings over time, there should be greater scope for shareholder returns to increase.

Foolish takeaway

For me, retirement would not mean giving up on growth.

I would want some dependable income, but I would also want businesses capable of becoming more valuable over the years ahead.

Wesfarmers, CBA, and Sigma each offer a different balance between those two goals, which is why I would be comfortable considering any of them for a long-term retirement portfolio.

The post 3 ASX shares I’d buy for income and growth in retirement appeared first on The Motley Fool Australia.

More reading

•  If I invest $10,000 in CBA shares, how much passive income will I receive in FY27?
• Down 22%: Are Wesfarmers shares now a good buy for passive income?
• Wesfarmers vs Telstra: Which ASX dividend stock comes out on top?
• How much passive income could I earn from a $650,000 superannuation balance?
• How to make $26,000 of passive income from ASX shares

Motley Fool contributor Grace Alvino has positions in Commonwealth Bank Of Australia and Wesfarmers. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Wesfarmers. The Motley Fool Australia has recommended Wesfarmers. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

James Hardie Industries Plc (ASX: JHX) shares are showing a little more life on Thursday.

The James Hardie share price is up 0.29% to $37.41 in late morning trade, but that barely dents its recent losses.

The stock has fallen almost 15% over the past month and more than 8% in a week, although it is still up around 21% in 2026.

Wednesday was particularly rough, with the shares dropping 5.23% after the company held its 2026 Investor Day.

Management reckons the company can keep growing strongly even if the US housing market stays weak.

But can it actually pull that off?

The US market remains difficult

The backdrop in the United States is still pretty tough.

US homebuilder sentiment fell to a 12-month low in September, while the average 30-year mortgage rate recently hit 6.76%.

Existing home sales also dropped 2% in August to an annualised rate of 3.98 million, the lowest level in 14 months.

That’s not exactly ideal when North America is still the biggest part of James Hardie’s business.

But management isn’t banking on cheaper mortgages or a housing rebound to drive growth.

At its Investor Day, James Hardie said it is targeting organic growth of 4% to 7% above the market over the longer term.

And the company reckons it can get there even if housing conditions stay weak.

Growth is still holding up

James Hardie’s first-quarter numbers suggest the plan is already starting to show through.

Q1 FY27 revenue rose 64% to US$1.48 billion, while pro-forma sales increased 12%.

North American fibre cement sales also grew 20% organically during the quarter, even with US housing still struggling.

That’s probably the number I’d be paying closest attention to from here.

If James Hardie can keep growing ahead of the housing market, it takes some of the pressure off waiting for a full recovery.

Can it keep this going?

The next few results should give investors a better idea of whether James Hardie can keep this up.

So far, the early signs are encouraging.

At $37.41, the shares are well below their August high of $44.12, despite the business still moving in the right direction.

If James Hardie can keep growing ahead of the wider housing market, I think investors could start looking at the stock a little differently.

And if US housing eventually improves as well, that would give the company another reason to keep growing.

The post James Hardie says it doesn’t need a US housing recovery. Can it prove it? appeared first on The Motley Fool Australia.

More reading

• Down 6% today: What’s going on with the James Hardie share price?
• James Hardie lifts guidance and details long-term growth at 2026 Investor Day
• Buy, hold, sell: Echo IQ, James Hardie, Woolworths shares
• Experts reckon this high-flying ASX 200 blue-chip stock is a buy
• This ASX 200 stock is up 30% in 2026. Here’s why I’d still buy it

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

CSL Ltd’s (ASX: CSL) board has admitted the financial performance of the business has been disappointing, but vowed to do better ahead of the company’s upcoming annual general meeting.

Aiming for improvement

In the notice of meeting lodged with the ASX, CSL chair Brian McNamee said the past year had been one of “significant change” for the blood products company, “and the board acknowledges that many shareholders are frustrated with the recent disappointing commercial and financial performance of the company”.

Mr McNamee added:

This includes reporting a multibillion-dollar statutory loss, driven by significant restructuring activity, leadership transition and the recognition of substantial non-cash balance sheet impairments. We built up substantial fixed costs, we were slow to adapt to competitive pressures, our research and development efforts didn’t deliver and some investments the Company made did not perform. We recognise this, and the management team is acting with urgency to earn back the confidence of shareholders through results.

Mr McNamee said the company’s core markets remained attractive, and the business was resilient and delivering strong cash flows.

He said the strategy was to invest in the core of the plasma business, “with selective investment beyond that”.

He added:

The industry fundamentals remain attractive. Plasma is a structurally stable therapeutic area, with durable demand and significant unmet patient need. CSL also maintains strength in influenza vaccines through the Seqirus business.

Mr McNamee said the board was encouraged by the early positive results of changes implemented by the management team.

He said the company needed to focus on stronger execution and adapt more rapidly as markets evolve.

Mr McNamee said the search for a new Chief Executive Officer was well-advanced, and in the meantime interim CEO Gordon Naylor was positioning the company for the next phase of growth.

CSL shares were 1 cent lower at $174.40 on Thursday. The shares have traded as low as $90 over the past year and as high as $222.47.

CSL shares looking like a good buy

Brokers are currently positive on the outlook for CSL following the company’s August results release.

RBC Capital Markets this week upgraded the company to an outperform rating with a $213 price target.

The broker said they now believed that “growth in the Behring business can offset the weak outlook in the Seqirus and Vifor business, and enable the company to deliver mid-single digit EPS growth for the next 3 years”.

The company is valued at $83.7 billion. The AGM will be held on Tuesday 27 October.

The post CSL acknowledges “disappointing” results but aims to do better appeared first on The Motley Fool Australia.

More reading

• CSL, Resmed, and more. See which ASX health stocks RBC Capital Markets has upgraded
• Two broker upgrades put CSL shares back in focus
• Is the CSL share price heading to $200?
• CSL shares have surged over 25%. Do brokers see more upside?
• CSL shares just fell 5% after a strong rally. Is the recovery losing steam?

Motley Fool contributor Cameron England has positions in CSL. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.